Literature DB >> 18820940

Detection of anti-envoplakin and anti-periplakin autoantibodies by ELISA in patients with paraneoplastic pemphigus.

Yongchu Huang1, Jing Li, Xuejun Zhu.   

Abstract

Paraneoplastic pemphigus patients (PNP) develop a group of autoantibodies, among which those against envoplakin and periplakin are almost always found. Epitope mapping has indicated that the linker subdomains of the proteins harbor the major antigenic sites recognized by PNP sera. In order to detect specific autoantibodies for the diagnosis of PNP, we expressed recombinant proteins containing linker subdomains of human periplakin and envoplakin in a human kidney cell line, and used them as the antigens for ELISAs. We found that all of the sera from 16 PNP patients recognized these two recombinant proteins by ELISA, and sera from 20 pemphigus vulgaris (PV), 12 pemphigus foliaceus (PF), 20 bullous pemphigoid (BP), 2 Castleman's tumor without PNP and 20 normal controls showed negative results. We also expressed the extracellular domain of desmoglein 3 (Dsg3) in the cell line, and used this recombinant Dsg3 as the ELISA antigen. Only 11 of our 16 PNP sera were positive, and most PV sera were positive. Our findings indicate that ELISAs using the recombinant proteins containing linker subdomains of envoplakin and periplakin expressed in a human cell line as the antigens are highly sensitive and specific for the diagnosis of PNP.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18820940     DOI: 10.1007/s00403-008-0901-y

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  6 in total

Review 1.  Novel therapies for pemphigus vulgaris: an overview.

Authors:  Oliver A Perez; Timothy Patton
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

2.  Frequency of Envoplakin and Type VII Collagen Autoantibodies and Co-occurrence with Other Skin-specific Autoantibodies in HIV-infected Patients and Uninfected Controls.

Authors:  René Reitermaier; Michael Skoll; Veronique Touzeau-Roemer; Maximilian C Aichelburg; Adelheid Elbe-Bürger; Wolfgang Bauer; Armin Rieger; Christopher Schuster
Journal:  Acta Derm Venereol       Date:  2021-11-24       Impact factor: 3.875

3.  Paraneoplastic Pemphigus: An Indication for Treatment in Chronic Lymphocytic Leukemia.

Authors:  Ifeanyichukwu Onukogu; Preethi Ramachandran; Joshua Narh; Sonu Sahni; Gardith Joseph
Journal:  Cureus       Date:  2020-05-27

4.  Mechanism of intermediate filament recognition by plakin repeat domains revealed by envoplakin targeting of vimentin.

Authors:  Claudia Fogl; Fiyaz Mohammed; Caezar Al-Jassar; Mark Jeeves; Timothy J Knowles; Penelope Rodriguez-Zamora; Scott A White; Elena Odintsova; Michael Overduin; Martyn Chidgey
Journal:  Nat Commun       Date:  2016-03-03       Impact factor: 14.919

Review 5.  Microtubule-Actin Crosslinking Factor 1 and Plakins as Therapeutic Drug Targets.

Authors:  Quincy A Quick
Journal:  Int J Mol Sci       Date:  2018-01-26       Impact factor: 5.923

6.  Binding of the periplakin linker requires vimentin acidic residues D176 and E187.

Authors:  Elena Odintsova; Fiyaz Mohammed; Catharine Trieber; Penelope Rodriguez-Zamora; Caezar Al-Jassar; Tzu-Han Huang; Claudia Fogl; Timothy Knowles; Pooja Sridhar; Jitendra Kumar; Mark Jeeves; Martyn Chidgey; Michael Overduin
Journal:  Commun Biol       Date:  2020-02-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.